2026-02-24
Alcohol, Aging, and Long-Term Health: What the Evidence Shows
Alcohol consumption interacts with aging biology in complex ways. This article covers the liver, brain, cardiovascular, and cancer evidence, plus what nutritional strategies can mitigate harm.
2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-24
Gut Barrier Integrity in Aging: Intestinal Permeability, Inflammaging, and Support
Age-related increases in intestinal permeability ("leaky gut") allow bacterial products including lipopolysaccharide (LPS) to enter systemic circulation, driving chronic low-grade inflammation associated with multiple aging-related conditions. Evidence-based interventions include dietary fiber, fermented foods, and specific probiotics — though research on reversing permeability changes in older humans is in early stages.
2026-02-24
Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress
Biological age testing spans conventional labs (HbA1c, CRP, lipids) to newer epigenetic clocks and proteomic aging scores. Most conventional biomarkers are actionable today; epigenetic clocks measure biological vs. chronological age but their clinical utility for intervention-guiding remains limited. A pragmatic panel of validated tests provides meaningful signal about longevity trajectory.
2026-02-20
Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis Update
Evidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.